Literature DB >> 3898942

Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis.

M C Bruce, L Poncz, J D Klinger, R C Stern, J F Tomashefski, D G Dearborn.   

Abstract

The risk for proteolysis of lung connective tissue was evaluated in patients with cystic fibrosis (CF) with chronic, severe lung infections by measuring uninhibited elastase activity in sputum samples and urinary excretion of desmosines (cross-linking amino acids in elastin). Of the 16 patients included in the study, 11 were infected with Pseudomonas aeruginosa, 2 with Pseudomonas cepacia, and 2 with both P. aeruginosa and P. cepacia. Uninhibited elastase activity (0.34 to 20.2 micrograms elastin degraded/mg protein/30 min) was detected in the sputum samples from each of 13 patients tested. Serine elastase activity was detected in the sputum of each of 12 patients, and metalloelastase (P. aeruginosa elastase and possibly macrophage elastase) activity was detected in the sputum of 11 of 12 patients tested. Male patients with CF excreted significantly more elastin cross-links (desmosines) in their urine than did control male subjects (3.6 +/- 1.7 micrograms/kg/24 h versus 1.5 +/- 0.6 micrograms/kg/24 h; p less than 0.01), and there was a significant correlation (p less than 0.05) between urine desmosine excretion and the severity of lung disease in the patients with CF as indicated by chest roentgenogram score. In 3 autopsied patients, abnormal elastin fibers were seen by light microscopy in all lung compartments. Fragmented and exfoliated elastin, evidence of active elastolysis, was noted in bronchial ulcers and abscesses. The results of this study suggest that proteolytic destruction of lung connective tissue is an ongoing process in the chronically infected CF lung and that this proteolysis contributes to the pathologic changes observed in airways and alveolar parenchyma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898942     DOI: 10.1164/arrd.1985.132.3.529

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  58 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 2.  Pathogenesis and management of lung disease in cystic fibrosis.

Authors:  M S Zach
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

Review 3.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 5.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets.

Authors:  G Döring; H Bareth; A Gairing; C Wolz; K Botzenhart
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

7.  Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

Authors:  V Thanasekaraan; M S Wiseman; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

Review 8.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

10.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.